1941 - Coadministration of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine With Influenza Vaccine in Older Adults

Presenting Author(s)

• 

  James A. Baber, MBChB, MPH (he/him/his)

  Senior Director
  Pfizer Vaccine Clinical Research
  Sydney, New South Wales, Australia

  Slides

Co-Author(s)

• KQ

  Karen Quan, BSc, MBBS, DPM

  Director
  Pfizer Vaccine Clinical Research
  Sydney, New South Wales, Australia
• EA

  Eugene Athan, MBBS, MPH, PhD

  Director/Professor
  Barwon Health
  Geelong, Victoria, Australia
• RS

  Robert Scott, MD

  University of the Sunshine Coast
  Morayfiled, Queensland, Australia
• AJ

  Anna Jaques, MPH

  Pfizer Vaccine Clinical Research
  Sydney, New South Wales, Australia
• QJ

  Qin Jiang, PhD

  Senior Director
  Pfizer
  Collegeville, Pennsylvania, United States
• WL

  Wen Li, PhD

  Pfizer Vaccine Clinical Research
  Collegeville, Pennsylvania, United States
• DC

  David Cooper, PhD

  Senior Director
  Pfizer
  Pearl River, New York, United States
• MC

  Mark W. Cutler, PhD

  Senior Director
  Pfizer Inc
  Pearl River, New York, United States
• EK

  Elena Kalinina, PhD

  Director
  Pfizer
  Pearl River, New York, United States
• AA

  Annaliesa S. Anderson, PhD

  SVP & CSO
  Pfizer
  New York, New York, United States
• KS

  Kena A. Swanson, Ph.D.

  Vice President, Viral Vaccines
  Pfizer
  Pearl River, New York, United States
• 

  William C. Gruber, MD

  SVP
  Pfizer
  Pearl River, New York, United States
• AG

  Alejandra C. Gurtman, M.D.

  Vice President
  Pfizer
  Pearl River, New York, United States
• BS

  Beate Schmoele-Thoma, MD

  Dr.
  Pfizer
  Pearl River, New York, United States